91��ɫ��Ƶ

July 6, 2026: 91��ɫ��Ƶ Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract

91��ɫ��Ƶ — Mon, 06 Jul 2026 14:57:57 +0000

91��ɫ��Ƶ Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract

Lyon, France, July 6, 2026 – 6:00 pm CET&�Բ��;– 91��ɫ��Ƶ (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies^TM(MET) dedicated to enhancing survival for patients with cancer through immune modulation, presents the results of its Annual and Extraordinary General Meeting held on Tuesday, June 16, 2026 at 9:30 am CET at the Company’s office and broadcasted live (replay available here). The Company also provides an update on the liquidity contract managed by Kepler Cheuvreux as of June 30^th, 2026.

Annual and Extraordinary General Meeting

The quorum reached by the shareholders present, representing, or voting remotely, was above 69.61% of voting shares.

Shareholders overwhelmingly approved most of the resolutions put forward by the Board of Directors by a majority of over 90%. The following resolutions were approved:

Approval of the financial statements for fiscal year 2025;
The renewal of the terms of office for current directors Mr. Jean-Marie Lefèvre, Mrs. Nadia Kamal, Mr. Claude Bertrand, Mr. Hervé Affagard, Mr. Jean Volatier, Seventure Partners and Bpifrance Investissement;
The compensation policy for corporate officers (Chairman, Chief Executive Officer and Directors) and the compensation paid or awarded during 2025 fiscal year – details of the votes on the said resolution is available on the Company’s website here;
Financial resolutions, notably delegations of authority to the Board of Directors to carry out capital increases in various situations.

Only one resolution was rejected:

Delegation of authority to the Board of Directors to decide on any merger, demerger or partial contribution of assets (29th resolution).

In accordance with the approval of resolutions 19 and 20, the Company also announced that the Board of Directors has decided to maintain the liquidity contract signed with Kepler Cheuvreux for the liquidity of the Company’s shares listed on Euronext Paris. Information on this contract is available in the Company’s Universal Registration Document (French only).

The full minutes of the Annual General Meeting and the results of the votes, resolution by resolution are available on the Company’s website in the Investors/ Shareholder Meetings’ section.

Half-year liquidity contract statement

Under the liquidity contract entered into between 91��ɫ��Ƶ and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30^th, 2026:

– 45,618 shares
– € 66,564.56

– Number of executions on buy side on semester: 2,998

– Number of executions on sell side on semester: 2,808

– Traded volume on buy side on semester: 222,290 shares for € 1,297,309.11

– Traded volume on sell side on semester: 203,219 shares for € 1,268,496.55

As a reminder :

the following resources appeared on the last half-year statement on 31 December 2025 on the liquidity account:
- 26,547 shares
- € 94,695.27
- Number of executions on buy side on semester: 2,120
- Number of executions on sell side on semester: 2,342
- Traded volume on buy side on semester: 74,642 shares for € 332,072.16
- Traded volume on sell side on semester: 83,855 shares for € 394,938.88

the following resources appeared on the liquidity account when the activity started:
- 0 shares
- € 200,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22^nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

—

About 91��ɫ��Ƶ
91��ɫ��Ƶ is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, 91��ɫ��Ƶ is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, 91��ɫ��Ƶ develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. 91��ɫ��Ƶ has been listed on Euronext Paris (ticker: MAAT) since 2021.

The post July 6, 2026: 91��ɫ��Ƶ Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract appeared first on 91��ɫ��Ƶ.

July 2nd, 2026: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

91��ɫ��Ƶ — Thu, 02 Jul 2026 16:07:29 +0000

Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF – Autorité des Marchés Financiers)

��

Lyon, France, July 2, 2026 – 6:30 pm CET��– 91��ɫ��Ƶ (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies^TM(MET) dedicated to enhancing survival for patients with cancer through immune modulation,��today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF)) on June 30, 2026.

Listing place: Euronext Paris

ISIN code: FR0012634822

Website:

��

Date	Total number of shares comprising the share capital	Total number of theoretical voting rights ⁽¹⁾	Total number of effective voting rights ⁽²⁾
06/30/26	18,863,543	18,863,543	18,817,925

��(1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
(2) Effective voting rights correspond to the total number of voting rights that may be used at a General Meeting. The total number of effective voting rights is calculated without taking into account the shares with suspended voting rights.

—

The post July 2nd, 2026: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital appeared first on 91��ɫ��Ƶ.

June 26, 2026: 91��ɫ��Ƶ Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease

91��ɫ��Ƶ — Fri, 26 Jun 2026 05:15:26 +0000

91��ɫ��Ƶ Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional Marketing Authorization Application (MAA) for MaaT013 (Xervyteg®), confirming the trend communicated in May 2026 after the Oral Explanation
91��ɫ��Ƶ plans to seek re-examination of the opinion and request that a Scientific Advisory Group (SAG) be convened
Second opinion upon re-examination expected during CHMP session in September 2026

��

Lyon, France, June 26, 2026 – 7:30 am CET��– 91��ɫ��Ƶ (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies^TM(MET) dedicated to enhancing survival for patients with cancer through immune modulation,��today announced that the CHMP of the EMA has adopted a negative opinion on the conditional MAA for MaaT013, under the brand name Xervyteg®, for the treatment of acute Graft-versus-Host Disease (aGvHD) in adult patients with gastrointestinal involvement refractory to prior lines of therapy. This confirms the previously announced negative trend opinion disclosed on May 20, 2026. The Company has reviewed grounds cited by the CHMP and confirms its plan to seek re-examination of the opinion as previously announced.

Under EMA procedures, the re-examination includes the appointment of a new rapporteur and co-rapporteur who will conduct a new and independent evaluation of the dossier. 91��ɫ��Ƶ will also request a Scientific Advisory Group (SAG) hearing with hematology experts on aGvHD to provide input and insights to the CHMP into, among other things, the clinical reality of managing aGvHD with complex concomitant therapies and patients in high need of solutions due to the severity of the disease and the lack of any other efficient third-line therapy so far.

In its opinion of June 25, 2026, the CHMP maintained the position that, given the use of concomitant therapies to manage aGvHD, the data package, primarily based on the ARES single-arm study, does not allow sufficient attribution of the observed clinical effect and safety to the study treatment alone.

Based on current EMA procedural timelines, a new CHMP opinion is expected within 60 days following validation of the re-examination request, with a second decision anticipated in the CHMP September Session (September 14-17, 2026).

91��ɫ��Ƶ remains confident in the clinical profile of MaaT013 (Xervyteg®), to treat a population with very limited treatment options and poor prognosis. This is supported by data from the ARES study, as well as data from the CHRONOS study () and real-world evidence from its Early Access Program, active in 13 countries, with more than 300 patients treated since 2019. The Company also confirms that the re-examination process has no impact on the ongoing Early Access Program, as of today, and that MaaT013 (Xervyteg®) remains available to eligible patients.

91��ɫ��Ƶ’s strategy also extends beyond MaaT013 (Xervyteg®), supported by the development of MaaT033, an oral microbiome therapy, currently evaluated in a randomized controlled Phase 2 trial for broader prophylactic and outpatient use in hemato-oncology, and by the expansion of its platform into immuno-oncology with the next generation product MaaT034.

—

About acute Graft-versus-Host Disease
Acute Graft-versus-Host Disease occurs in patients within 100 days of undergoing a stem cell or bone marrow transplant, where the transplanted cells initiate an immune response and attack the transplant recipient’s organs, causing inflammation of the skin, liver and/or gastrointestinal tract and leading to significant morbidity and mortality. GI involvement is associated with severe complications such as profound diarrhea, abdominal pain, intestinal bleeding, and death. These complications are often life-threatening, with increased mortality risk, due to the challenges of managing severe GI inflammation and the associated risks of infection, malnutrition, and organ failure. The standard first-line therapy for treating aGvHD is the use of systemic steroids. If patients do not respond to steroids, they are considered steroid resistant (SR) and other agents can be administered. Currently, ruxolitinib is the standard second-line treatment for steroid-refractory acute graft-versus-host disease. More recently, remestemcel L (rknd) was approved in December 2024 in the United States, specifically for use in the pediatric population as a second-line treatment.

About MaaT013 (Xervyteg®)
91��ɫ��Ƶ’s Microbiome Ecosystem Therapies (MET) are designed to leverage a full microbiome ecosystem to restore balance and maximize clinical benefits for patients with severe, treatment-induced dysbiosis in acute diseases. MaaT013 (Xervyteg®) is a full-ecosystem, off-the-shelf, standardized, pooled-donors, enema Microbiome Ecosystem TherapyTM for acute, hospital use. It is characterized by a consistently high diversity and richness of microbial species and the presence of ButycoreTM (a group of bacterial species known to produce anti-inflammatory metabolites). Xervyteg® (MaaT013) aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce the symptoms of steroid-resistant, gastrointestinal (GI)-aGvHD. Xervyteg® (MaaT013) has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Forward-looking Statements
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim”, “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

The post June 26, 2026: 91��ɫ��Ƶ Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease appeared first on 91��ɫ��Ƶ.

May 26, 2026: 91��ɫ��Ƶ Provides Business Update and Reports Financial Results for the First Quarter 2026

91��ɫ��Ƶ — Tue, 26 May 2026 16:42:35 +0000

91��ɫ��Ƶ Provides Business Update and Reports Financial Results for the First Quarter 2026

MaaT013 (Xervyteg®):
- In May 2026, the Company was informed of a “negative trend” opinion on its Marketing Authorization Application from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), ahead of the expected CHMP formal vote in June; the Company plans to request a re-examination procedure upon the formal opinion
- EBMT 2026 annual congress: 91��ɫ��Ƶ presented data from the pivotal ARES trial of MaaT013 (Xervyteg®) featured in the Presidential Session oral presentation and 3 posters (PHOEBUS, CHRONOS and THRASSA)
Revenues of €0.8 million in the first quarter of 2026 derived from the Early Access Program
As of March 31, 2026, cash and cash equivalents were €18.1 million
Cash runway extension to November 2026

��

Lyon, France, May 26, 2026 – 7:00 pm CET��– 91��ɫ��Ƶ (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies^TM(MET) dedicated to enhancing survival for patients with cancer through immune modulation,��today provided a business update and reported its cash position as of March 31, 2026.

“During the first quarter of 2026, we continued to execute with financial discipline while supporting the advancement of our clinical and regulatory priorities. The drawdown of EIB Tranche B, combined with ongoing operational optimization, has extended our cash runway into November 2026 supporting the upcoming regulatory steps, including the planned re-examination of the Marketing Authorization Application for MaaT013 (Xervyteg®),” stated Eric Soyer, CFO of 91��ɫ��Ƶ.

��

Pipeline highlights

In Hemato-Oncology

Acute Graft-versus-Host Disease (aGvHD) – MaaT013 (Xervyteg^®)

In January 2026, 91��ɫ��Ƶ transitioned the Early Access Program in Europe to Clinigen, allowing 91��ɫ��Ƶ to leverage the infrastructure of Clinigen and start expanding patient access. The Company has treated approximately 230+ patients under the Early Access Program in 13 different countries to date, and data from the EAP has been presented at major medical congresses.
In March 2026, during the EBMT 2026 annual congress:
- The final results of the ARES pivotal trial evaluating MaaT013 (Xervyteg^®) in aGvHD were presented during an oral presentation during the presidential symposium at EBMT 2026 Annual Congress on March 23, 2026.
- 91��ɫ��Ƶ‘s strategic partner Clinigen hosted a dedicated Industry Symposium on advancing care for steroid-refractory gastrointestinal aGvHD, in the context of the transition in January 2026 of the EAP program to Clinigen, and the ongoing commercial readiness activities, subject to the marketing approval of MaaT013 (Xervyteg^®).
- The Company also presented results from the CHRONOS study, one of the largest real-world studies including refractory GI-aGvHD patients (n=59) treated with third-line best available treatments other than microbiome-based therapy, and announced publication in April 2026 of those retrospective data in Bone Marrow Transplantation Journal. Results from CHRONOS included 29% 12-month overall survival and 37% Day-28 GI-overall response rate, thus supporting the urgent need for new therapeutic options in this indication.

MaaT013 (Xervyteg^®) Regulatory Plan:
- As a post period event, 91��ɫ��Ƶ announced in May 2026 that during the Oral Explanation with EMA’s CHMP, the Company was informed of a “negative trend” in relation with the upcoming June 2026 CHMP vote. Subject to the formal vote at the June 2026 CHMP meeting, the Company intends to request a re-examination of the application.
- As previously announced, the U.S. development plan remains underway, with no material cash impact, to ensure a potential launch in a timely manner of the future clinical study in the U.S, subject to appropriate funding and regulatory, clinical, and operational readiness.
- Additionally, the Company continues to expand its U.S. footprint through its EAP, with recurring patient requests from leading hospitals such as City of Hope (Duarte- Los Angeles, CA), Massachusetts General Hospital (Boston, MA), the University of Alabama Hospital (Birmingham, AL), Miami Cancer Institute (Miami, FL), Chicago Medical Center (Chicago, IL) and Advocate Lutheran Hospital (Park Ridge, IL).

��

Allogenic Hematopoietic Stem Cell Transplant (allo-HSCT) – MaaT033

In January 2026, as a post period event, a third routine evaluation was conducted and reconfirmed the favorable safety profile of MaaT033 in this trial. The Phase 2 PHOEBUS trial is ongoing and is potentially pivotal in Europe. Topline results (1-year overall survival) are expected in Q4 2028.
In March 2026, the Company presented a poster of the PHOEBUS Phase 2 trial during the EBMT 2026 annual congress, detailing the design and the favorable safety profile confirmed by the 5 DSMBs assessments since 2025.

��

In Immuno-Oncology

MaaT034 – Next-generation drug candidates with co-cultured technology

In 2026, the Company is focusing on GMP batch production and regulatory readiness and targets to initiate a First-in- Human trial in 2027, subject to appropriate funding, with a development strategy that will place a particular focus on the U.S. market.
In January 2026, 91��ɫ��Ƶ announced that the first patient was randomized in the IMMUNOLIFE trial evaluating the potential of MaaT033 in combination with Regeneron’s Cemiplimab in enhancing disease control rate versus best investigator’s choice in patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance to PD-1/PD-L1 blockade following antibiotic (ATB) exposure and who present ATB-induced gut dysbiosis. The Company was also informed by PICASSO’s academic sponsor that topline results could be expected in H1 2026. However, the timing remains subject to the sponsor’s discretion and the Company has no control over the study results communication timelines. The PICASSO expected data are intended to provide complementary insights only and do not directly impact MaaT034’s development strategy.

��

Cash position^[1]��

As of March 31, 2026, total cash and cash equivalents were EUR 18.1 million (as compared to EUR 24.9 million as of December 31, 2025), not including the drawdown in April 2026 of Tranche B (EUR 6 million) of the European Investment Bank (EIB) loan financing.
The Company has taken cash management measures to extend its financial visibility into November 2026 (vs August 2026), covering the upcoming regulatory milestones including the re-examination process, while continuing to advance its pipeline.

��

Revenues in Q1 2026¹

91��ɫ��Ƶ reported revenues of EUR 0.8 million for the first quarter of 2026 (reported EAP revenues were EUR 1.1 million for the same period of 2025).
Since January 2026 and the transition to the EAP program to Clinigen, 91��ɫ��Ƶ is now selling the product to Clinigen, which then supplies hospitals in Europe. As a result, revenues generated by the Company are now based on the financial terms of the licensing agreement. Consequently, the net income reported by 91��ɫ��Ƶ in Q1 2026, based on transfer price and royalties, was EUR 0.8 million, and would have been EUR 1.3 million pre-transition.
The slight decrease in reported revenues was therefore mostly attributable to the change in revenue accounting. On a same like-for-like basis, revenues generated by MaaT013 (Xervyteg^®) in Q1 2026 reflected a 19% increase year-over-year, underlining the sustained demand for the product.

��

Financial calendar*

June 16, 2026: Annual General Meeting
September 29, 2026: Publication of H1 2026 results
November 16, 2026: Publication of revenues & cash for Q3 2026

*Indicative calendar that may be subject to change. ��

��

Availability of the Documents Preparatory to the Annual General Meeting

The Company’s shareholders are invited to attend the Combined General Meeting to be held on Tuesday, June 16, 2026, at 9:30 a.m. at the Company’s offices, 70 avenue Tony Garnier – 69007 Lyon, France.
The preliminary notice of meeting, including the agenda and draft resolutions, was published in the Bulletin des Annonces Légales et Obligatoires (BALO) No. 56 dated May 11, 2026, and the notice of meeting will be published in the legal gazette “Le Tout Lyon” on May 27, 2026.
As of today, all information and documents referred to in Articles R. 22-10-23, R. 225-81 and R. 225-83 of the French Commercial Code are available on the Company’s website: maatpharma.com
In accordance with Articles L. 225-115 and R. 225-83 of the French Commercial Code, the full text of the documents to be presented at the General Meeting will also be made available at the Company’s registered office.
The General Meeting will be broadcast live in full by video, and the connection details will be available on the Company’s website. A replay will be made available no later than seven business days after the General Meeting has been held.

��

Upcoming conferences participation*

June 24-25, 2026 – Portzamparc Conference Mid & Small Caps 2026, Paris

*Indicative calendar that may be subject to change.

��

[1] unaudited financial results

—

About 91��ɫ��Ƶ
91��ɫ��Ƶ is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.��As a pioneer, 91��ɫ��Ƶ is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, 91��ɫ��Ƶ develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. 91��ɫ��Ƶ has been listed on Euronext Paris (ticker: MAAT) since 2021.

��

The post May 26, 2026: 91��ɫ��Ƶ Provides Business Update and Reports Financial Results for the First Quarter 2026 appeared first on 91��ɫ��Ƶ.

May 20, 2026: 91��ɫ��Ƶ Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease

91��ɫ��Ƶ — Wed, 20 May 2026 18:42:29 +0000

91��ɫ��Ƶ Announces Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease

During the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) Oral Explanation, the Company received a “negative trend” opinion for the upcoming June CHMP vote
Subject to the formal CHMP vote expected in the June Meeting, the Company plans to request a re-examination procedure for the application

��

Lyon, France, May 20, 2026 – 8:45pm CET��– 91��ɫ��Ƶ (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies^TM(MET) dedicated to enhancing survival for patients with cancer through immune modulation, today it has been informed by the CHMP of the EMA of a “negative trend” opinion on its conditional Marketing Authorization Application (MAA) for MaaT013 (Xervyteg®) for the treatment of acute Graft-versus-Host Disease (aGvHD), following its recent CHMP oral explanation.

The CHMP formal vote is expected at the upcoming June Meeting, and subject to the formal vote, the Company intends to request a re-examination of the application, a standard procedure enabling a new independent scientific assessment by a different set of reviewers. The EMA’s procedure provides that the CHMP shall re-examine its opinion within 60 calendar days following receipt of the Company’s official request for re-examination.

“We continue to strongly believe in the potential for registration of MaaT013 (Xervyteg®). We remain committed to working closely with the EMA to progress this application, encouraged by the therapy’s potential to address the significant unmet medical need in patients with aGvHD and by the continued support from the hematology community,” said Hervé Affagard, CEO and co-founder of 91��ɫ��Ƶ.��“Our application remains under review, and we are fully committed to engaging constructively in the re-examination process.”

For context, the CHMP feedback shared during the Oral Explanation reflects challenges, in the Company’s view, expected for first-in-class therapies based on a novel therapeutic approach, particularly those based on a single-arm pivotal trial. The application for MaaT013 (Xervyteg®) is assessed under the Conditional Marketing Authorization (CMA) pathway, which is designed to facilitate earlier access to medicines addressing unmet medical needs while confirmatory data is generated post-approval.

The Company is taking cash management measures to extend its financial visibility into November 2026 (vs August 2026), covering the upcoming regulatory milestones including the re-examination process, while continuing to advance its pipeline.

MaaT013 (Xervyteg®) is supported by clinical data from the pivotal ARES study, and real-world data with the ongoing Early Access Program active in 13 countries and with 300+ patients globally treated to date since 2019. Data supporting MaaT013 (Xervyteg®) has previously been presented at major international congresses and in peer-reviewed publications. The Company remains committed to advancing MaaT013 (Xervyteg®) through the European regulatory process, expanding patient access and progressing its broader pipeline in microbiome-based in oncology.

—

About 91��ɫ��Ƶ
91��ɫ��Ƶ is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.��As a pioneer, 91��ɫ��Ƶ is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, 91��ɫ��Ƶ develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. 91��ɫ��Ƶ has been listed on Euronext Paris (ticker: MAAT) since 2021.

About acute Graft-versus-Host Disease
Acute Graft-versus-Host Disease occurs in patients within 100 days of undergoing a stem cell or bone marrow transplant, where the transplanted cells initiate an immune response and attack the transplant recipient’s organs, causing inflammation of the skin, liver and/or gastrointestinal tract and leading to significant morbidity and mortality. GI involvement is associated with severe complications such as profound diarrhea, abdominal pain, intestinal bleeding, and death. These complications are often life-threatening, with increased mortality risk, due to the challenges of managing severe GI inflammation and the associated risks of infection, malnutrition, and organ failure. The standard first-line therapy for treating aGvHD is the use of systemic steroids. If patients do not respond to steroids, they are considered steroid resistant (SR) and other agents can be administered. Currently the only agent approved for treating SR aGvHD after failure of steroid treatment is ruxolitinib, which is currently approved for this indication in USA and has received approval from the European Medicines Agency’s Committee for Human Medicinal Products (CHMP) on March 25, 2022.

About Xervyteg® (MaaT013)
91��ɫ��Ƶ’s Microbiome Ecosystem Therapies (MET) are designed to leverage a full microbiome ecosystem to restore balance and maximize clinical benefits for patients with severe, treatment-induced dysbiosis in acute diseases. MaaT013��is currently under regulatory review by the relevant authorities and has not yet received marketing authorization. ��MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donors, enema Microbiome Ecosystem Therapy^TM for acute, hospital use. It is characterized by a consistently high diversity and richness of microbial species and the presence of Butycore^TM (a group of bacterial species known to produce anti-inflammatory metabolites). MaaT013 aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal (GI)-aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The post May 20, 2026: 91��ɫ��Ƶ Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease appeared first on 91��ɫ��Ƶ.

May 11, 2026: 91��ɫ��Ƶ to Hold Annual General Meeting on June 16, 2026

91��ɫ��Ƶ — Mon, 11 May 2026 15:55:39 +0000

91��ɫ��Ƶ to Hold Annual General Meeting on June 16, 2026

Lyon, France, May 11, 2026 – 6:00pm CET – 91��ɫ��Ƶ (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies^TM(MET) dedicated to enhancing survival for patients with cancer through immune modulation, informs its shareholders that the Annual General Meeting (ordinary and extraordinary) will be held on June 16, 2026, at 9:30am CET at the Company’s headquarter in France located at 70 avenue Tony Garnier, 69007 Lyon and will also be broadcasted live.

The notice of meeting, serving as convening notice is published in the Bulletin des annonces légales obligatoires on Monday, 11 May 2026 (), in bulletin no. 56 (reference 2601636). It contains the detailed agenda, the draft resolutions and the main terms and conditions of participation and voting at this meeting.

The convening notice will be published in the Journal des annonces légales “Le Tout Lyon” on 27 May 2026. It will also be sent to registered shareholders and made available to institutions holding bearer shares.

The documents and information relating to this General Meeting have been and will be, in accordance with the applicable laws and regulations:

posted on 91��ɫ��Ƶ’s website (www.maatpharma.com/investors) under the section “Investors/General Meetings/2026”;
made available to shareholders at the Company’s registered office at 70 avenue Tony Garnier, 69007 Lyon, France;
and sent to shareholders by Uptevia – Service Assemblées Générales, 90 – 110 Esplanade du Général de Gaulle – 92931 Paris La Défense Cedex, on receipt of their request.

��

Further information on this General Meeting, and on how shareholders can vote, is available on 91��ɫ��Ƶ’s website under the Investors section (“Participating in the General Meeting”).
The General Meeting will be broadcast live via a dedicated platform and can be accessed through the link . A recording of the General Meeting will be made available on the Company’s website within the timeframe required by applicable regulations.

Financial Calendar*

• May 26, 2026: Publication of Q1 2026 revenue and cash position
• June 16, 2026: Annual General Meeting
• September 15, 2026: Publication of H1 2026 results
• November 16, 2026: Publication of Q3 2026 revenue and cash position
(*Indicative calendar that may be subject to change.)

—

About 91��ɫ��Ƶ
91��ɫ��Ƶ is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.��As a pioneer, 91��ɫ��Ƶ is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, 91��ɫ��Ƶ develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. 91��ɫ��Ƶ has been listed on Euronext Paris (ticker: MAAT) since 2021.